[{"orgOrder":0,"company":"Valorum Biologics","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2025","type":"Licensing Agreement","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony-stimulating factor receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Valorum Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valorum Biologics \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Valorum Biologics \/ Lupin Ltd"}]

Find Clinical Drug Pipeline Developments & Deals by Valorum Biologics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          VMX
                          Not Confirmed
                          VMX
                          Not Confirmed

                          Details : Through the licensing deal for Pegfilgrastim, the agreement aims to advance the treatment of neutropenia by targeting the Granulocyte colony-stimulating factor receptor.

                          Product Name : Armlupeg

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          December 04, 2025

                          Lead Product(s) : Pegfilgrastim,Undisclosed

                          Therapeutic Area : Hematology

                          Highest Development Status : Approved FDF

                          Sponsor : Lupin Ltd

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank